About Tamara Lotan
PTEN (phosphatase and tensin homologue on chromosome 10) is a tumor suppressor that is commonly lost in several cancers. Loss of PTEN is one of the most common molecular aberrations in prostate cancer and is frequently associated with high risk disease. Routine and accurate identification PTEN inactivation may potentially serve as a prognostic biomarker in prostate cancer and might also help select appropriate treatment for patients. Dr. Lotan has developed a sensitive assay to detect PTEN loss in prostate cancer. This test will assist pathologists in identifying early, potentially aggressive prostate cancer, the results of which will inform decisions on personalizing therapy.
The 2011 Elaine Wynn – PCF Young Investigator Award
Tamara Lotan, MD
Johns Hopkins University
Angelo DeMarzo, MD, PhD and Elizabeth Platz, ScD